[go: up one dir, main page]

AR035959A1 - Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion - Google Patents

Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion

Info

Publication number
AR035959A1
AR035959A1 ARP020101441A ARP020101441A AR035959A1 AR 035959 A1 AR035959 A1 AR 035959A1 AR P020101441 A ARP020101441 A AR P020101441A AR P020101441 A ARP020101441 A AR P020101441A AR 035959 A1 AR035959 A1 AR 035959A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
alkenyl
compounds
Prior art date
Application number
ARP020101441A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR035959A1 publication Critical patent/AR035959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la cual: R1 es seleccionado entre el grupo que consiste en alquilo C1-8, alquenilo C2-8, R42N-alquilo C1-6, R42NC(=O)-alquilo C1-6, R4O-alquilo C1-6, R4OC(=O)-alquilo C1-6, R4C(=O)-alquilo C1-6, R4C(=O)NR4-alquilo C1-6, R42NSO2-alquilo C1-6, R4CSO2NR4-alquilo C1-6, R42NC(=O)NR4-alquilo C1-6, R42NSO2NR4-alquilo C1-6, aril-alquilo C1-6, aroil-alquilo C1-6, heteroaril-alquilo C1-6, heteroaroil-alquilo C1-6, heterocicloalquil C3-8- alquilo C1-6, heteroaril-alquilo C1-6 bicíclico y heteroaroil- alquilo C1-6 bicíclico; las porciones R1 comprenden alquenilo C2-8 no sustituido y alquilo C1-8 no sustituido o sustituido con una o más porciones seleccionadas independientemente del grupo que consiste en halógeno, ciano, acetoximetilo y nitro; Ar es una porción arilo optativamente sustituida; R2 es alquilo C1-6 no sustituido o sustituido en los carbonos 1-6 con uno o más sustituyentes flúor o cicloalquilo C3-6; R3 se selecciona del grupo que consiste en: fórmulas (2), (3), (4), (5), (6), (7), (8) y (9); R4 es una porción seleccionada independientemente del grupo que consiste en -H, -alquilo C1-6, -alquenilo C2-6 y -alquinilo C2-6; las porciones R5 se seleccionan independientemente del grupo que consiste en -H, -alquilo C1-6, -alquenilo C2-6 y heterociclilo; las porciones R6 se seleccionan independientemente del grupo que consiste en: -H, -alquilo C1-6, -alquenilo C2-6 y alcanoílo C1-6, heterociclilo, heterociclil-alquilo C1-3, arilo, aril-alquilo C1-3, heteroarilo, heteroaril-alquilo C1-3, heteroarilo bicíclico, y heteroaril-alquilo C1-3 bicíclico; R5 y R6 pueden combinarse para formar un heterociclo de 5-7 miembros; X se selecciona del grupo que consiste en -C(R5)2-, -NR5-, C(=O)-, -CH2-CH2-, -CH=CH-, -O-, -C(R)(R')-, y -S(O)n- (donde n = 0, 1 o 2), donde R y R' = alquilo C1-6, OR'', o H, y R'' = H o alquilo C1-6; e Y es carbono o nitrógeno, en donde si R1 representa R42N-alquilo C1-6, en donde ambas apariciones de R4 representan -alquilo C1-6 entonces R3 no es acetilo, -NH2 o acetamido. Uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composición farmacéutica, y método de reducción
ARP020101441A 2001-04-20 2002-04-19 Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion AR035959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101387A SE0101387D0 (sv) 2001-04-20 2001-04-20 Novel compounds

Publications (1)

Publication Number Publication Date
AR035959A1 true AR035959A1 (es) 2004-07-28

Family

ID=20283822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101441A AR035959A1 (es) 2001-04-20 2002-04-19 Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion

Country Status (25)

Country Link
US (2) US7030139B2 (es)
EP (1) EP1390350A1 (es)
JP (1) JP2004528334A (es)
KR (1) KR20040022421A (es)
CN (1) CN1250531C (es)
AR (1) AR035959A1 (es)
BG (1) BG108271A (es)
BR (1) BR0208907A (es)
CA (1) CA2444381A1 (es)
CZ (1) CZ20032833A3 (es)
EE (1) EE200300524A (es)
HU (1) HUP0303825A3 (es)
IL (1) IL158142A0 (es)
IS (1) IS6971A (es)
MX (1) MXPA03009558A (es)
MY (1) MY134568A (es)
NO (1) NO20034665L (es)
NZ (1) NZ528403A (es)
PL (1) PL366517A1 (es)
RU (1) RU2312864C2 (es)
SE (1) SE0101387D0 (es)
SK (1) SK13032003A3 (es)
UA (1) UA76743C2 (es)
WO (1) WO2002085866A1 (es)
ZA (1) ZA200307752B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301698D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR101138673B1 (ko) * 2003-06-26 2012-04-24 다케다 야쿠힌 고교 가부시키가이샤 칸나비노이드 수용체 조절제
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1675822A2 (en) * 2003-10-16 2006-07-05 Cara Therapeutics, Inc. Amide or thioamide derivatives and their use in the treatment of pain
RU2374234C2 (ru) * 2004-09-24 2009-11-27 Астразенека Аб Бензимидазольные производные, содержащие их композиции, их получение и применение
EP1797075A1 (en) * 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
WO2006033630A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
WO2006033628A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2581232C (en) * 2004-09-24 2015-04-07 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514589A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉｉ
JP2008514595A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それを含有する組成物、その製造及びその使用ｉｉ
WO2006033632A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
CN101031563A (zh) * 2004-09-24 2007-09-05 阿斯利康(瑞典)有限公司 苯并咪唑衍生物、含有它们的组合物、其制备方法和用途
ES2309812T3 (es) * 2004-10-27 2008-12-16 F. Hoffmann-La Roche Ag Nuevos derivados de indol o benzimidazol.
WO2006048754A1 (en) * 2004-11-02 2006-05-11 Pfizer Japan Inc. Sulfonyl benzimidazole derivatives
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
WO2006097808A1 (en) * 2005-03-15 2006-09-21 Pfizer Japan Inc. Benzimidazolone derivatives as cb2 receptor ligands
JP2008539246A (ja) 2005-04-28 2008-11-13 フェリング ベスローテン フェンノートシャップ Ｉｂｄ治療のための新規化合物の使用
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007091950A1 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
US7700618B2 (en) 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
AU2007271241A1 (en) 2006-07-04 2008-01-10 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2907784B1 (fr) * 2006-10-27 2009-02-13 Sod Conseils Rech Applic Derives phenyliques et leur utilisation comme medicament
WO2009116074A2 (en) * 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
EP2456428A1 (en) 2009-07-23 2012-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
AU2011218316B2 (en) 2010-02-18 2015-08-20 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US9181226B2 (en) * 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
CN102977056B (zh) * 2012-11-28 2014-11-26 深圳万乐药业有限公司 N-苄氧羰基-3-氟-4-吗啉基苯胺的合成方法
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2017157332A1 (zh) * 2016-03-18 2017-09-21 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945044A (en) * 1957-07-12 1960-07-12 Ciba Pharm Prod Inc Certain 1-(diethyl-aminoethyl), 5-amino, 2-benzyl or substituted benzyl, benzimidazoles
FR1481049A (fr) * 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
US5620978A (en) * 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP1390350A1 (en) 2004-02-25
HUP0303825A3 (en) 2005-06-28
BR0208907A (pt) 2004-04-20
IL158142A0 (en) 2004-03-28
NO20034665D0 (no) 2003-10-17
SK13032003A3 (sk) 2005-01-03
MXPA03009558A (es) 2004-02-12
EE200300524A (et) 2004-02-16
CZ20032833A3 (en) 2004-05-12
ZA200307752B (en) 2005-01-03
PL366517A1 (en) 2005-02-07
IS6971A (is) 2003-09-29
WO2002085866A1 (en) 2002-10-31
JP2004528334A (ja) 2004-09-16
BG108271A (bg) 2004-12-30
NO20034665L (no) 2003-12-10
SE0101387D0 (sv) 2001-04-20
US20060135554A1 (en) 2006-06-22
CA2444381A1 (en) 2002-10-31
UA76743C2 (uk) 2006-09-15
CN1503787A (zh) 2004-06-09
MY134568A (en) 2007-12-31
US7030139B2 (en) 2006-04-18
HUP0303825A2 (hu) 2004-03-01
RU2003129638A (ru) 2005-04-10
US20040116465A1 (en) 2004-06-17
KR20040022421A (ko) 2004-03-12
NZ528403A (en) 2005-05-27
CN1250531C (zh) 2006-04-12
RU2312864C2 (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
AR035959A1 (es) Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion
HUP0203872A2 (hu) Helyettesített 4-(fenil-N-alkil)-piperazin és piperidinszármazékok, alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
FI20000085A (fi) Menetelmä terapeuttisesti aktiivisten 4-amino-substituoitujen 2-azabicyklo/3.3.1/nonaanijohdannaisten valmistamiseksi
IS4206A (is) Hliðstæðar aðferðir til framleiðslu á andróstenónafleiðu og milliefni notuð í aðferðunum
PT74563B (en) Process for preparing benzamide derivatives and pharmaceutical compositions containing the same
AR045822A1 (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos
KR920018030A (ko) 치환된 이미다졸-2-온의 유도체 및 이의 제조방법
AR045820A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos
RU95101437A (ru) Содержащее производные 3-фенилсульфонил-3,7-диазабицикло [3,3,1] нонана лекарственное средство, способ получения производных 3-фенилсульфонил-3,7-диазабицикло-[3,3,1]-нонана
ATE204278T1 (de) Serotoninergische ergolin derivate
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
KR920016456A (ko) 5-(치환 아미노) -1,2,4-트리아졸로 [1,5-a]피리미딘 유도체
AR035698A1 (es) Derivados de guanidina biciclicos, procedimiento para preparar estos compuestos y composicion farmaceutica
AR012435A1 (es) Compuesto de 4-aminopirido[2,3-d]pirimidina 6,7-disustituida; el uso del mismo para la manufactura de un medicamento, procedimiento para su preparacion,composicion farmaceutica que lo contiene, compuestos intermediarios y procedimiento para su preparacion.
ATE22081T1 (de) Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
NO151587C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater
DE3481059D1 (de) Neue 11-piperazinyl-5h-imidazo(2,1-c)(1,4)benzodiazepine, verfahren zu ihrer herstellung und zwischenprodukte und erstere enthaltende arzneimittel.
NO833665L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroksy-2h-1,2-benzotiazin-3-karboksamid-1,1-dioksyd-derivater
AR026597A1 (es) Derivados de pirimidina
ES527550A0 (es) Procedimiento para la preparacion de derivados de acridanona
TH66682A (th) แอนตาโกนิสท์ของเบนซิมิดาโซโลนฮิสตามีน h3
TH10903B (th) [(เบนโซไดออกซาน, เบนโซฟิวราน หรือเบนโซพิราน)แอลคิลอะมิโน] แอลคิล ซับสทิทิวเทด กัวนิดีน ในฐานะเป็นสารที่เลือกเฉพาะทำการให้หลอดโลหิตตีบตัว

Legal Events

Date Code Title Description
FA Abandonment or withdrawal